MedTrace Logo

Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men

NCT05636904 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-04-08

No results posted yet for this study

Summary

The goal of this study is to measure the safety, tolerability, and the hair growth response to topical DLQ01 solutions in comparison to the vehicle and a comparator solution in 120 males with Androgenetic Alopecia.

Conditions

Interventions

DRUG

prostaglandin F2a analogue in vehicle solution high dose

Topical treatment for 24 weeks

DRUG

prostaglandin F2a analogue in vehicle solution low dose

Topical treatment for 24 weeks

DRUG

active ingredient-free vehicle solution to DLQ01

Topical treatment for 24 weeks

DRUG

Minoxidil 5% Topical Solution

Topical treatment for 24 weeks

Sponsors & Collaborators

  • Dermaliq Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Betsy Hughes-Formella, PhD · Dermaliq Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-05
Primary Completion
2024-03-28
Completion
2024-03-28

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05636904 on ClinicalTrials.gov